Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models

The Journal of Clinical Investigation
Alex McCampbellJessica Amacker

Abstract

Mutations in superoxide dismutase 1 (SOD1) are responsible for 20% of familial ALS. Given the gain of toxic function in this dominantly inherited disease, lowering SOD1 mRNA and protein is predicted to provide therapeutic benefit. An early generation antisense oligonucleotide (ASO) targeting SOD1 was identified and tested in a phase I human clinical trial, based on modest protection in animal models of SOD1 ALS. Although the clinical trial provided encouraging safety data, the drug was not advanced because there was progress in designing other, more potent ASOs for CNS application. We have developed next-generation SOD1 ASOs that more potently reduce SOD1 mRNA and protein and extend survival by more than 50 days in SOD1G93A rats and by almost 40 days in SOD1G93A mice. We demonstrated that the initial loss of compound muscle action potential in SOD1G93A mice is reversed after a single dose of SOD1 ASO. Furthermore, increases in serum phospho-neurofilament heavy chain levels, a promising biomarker for ALS, are stopped by SOD1 ASO therapy. These results define a highly potent, new SOD1 ASO ready for human clinical trial and suggest that at least some components of muscle response can be reversed by therapy.

References

Oct 1, 1996·Neuropathology and Applied Neurobiology·L I Bruijn, D W Cleveland
Dec 13, 2005·Journal of Neuroscience Research·Arifumi MatsumotoHideyuki Okano
Aug 1, 2006·The Journal of Clinical Investigation·Richard A SmithDon W Cleveland
Feb 6, 2007·Proceedings of the National Academy of Sciences of the United States of America·Makoto UrushitaniJean-Pierre Julien
May 9, 2007·Nature Medicine·Rishi RakhitAvijit Chakrabartty
Feb 13, 2008·Archives of Neurology·Timothy M MillerBrian K Kaspar
Mar 1, 2011·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Renzo MancusoXavier Navarro
Mar 29, 2012·Methods in Molecular Biology·Yimin Hua, Adrian R Krainer
Jun 30, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Hsueh-Ning LiuJanice Robertson
Sep 19, 2012·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Dale J LangeDaniel Benjamin
May 21, 2013·Brain : a Journal of Neurology·Rachele A SacconPietro Fratta
Aug 2, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Sarah L DeVosTimothy M Miller
Sep 7, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kevin D FoustBrian K Kaspar
Oct 25, 2013·Science Translational Medicine·Dhruv SareenRobert H Baloh
Oct 31, 2013·Proceedings of the National Academy of Sciences of the United States of America·Clotilde Lagier-TourenneJohn Ravits
Nov 21, 2014·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Gretchen M ThomsenClive N Svendsen
Jun 16, 2015·The Journal of Clinical Investigation·Matthew J CrispTimothy M Miller
May 24, 2016·Neuron·Kathleen M SchochTimothy M Miller
Jun 5, 2016·Journal of Neurology, Neurosurgery, and Psychiatry·Taha BaliTimothy M Miller
Oct 30, 2016·Proceedings of the National Academy of Sciences of the United States of America·Laura FerraiuoloBrian K Kaspar
Jan 27, 2017·Science Translational Medicine·Sarah L DeVosTimothy M Miller
Feb 7, 2017·Journal of Neuroscience Methods·Curt MazurEd Wancewicz
Mar 2, 2017·Acta Neuropathologica·Sandrine Da CruzJohn Ravits
Apr 19, 2017·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Mariah L HoyeTimothy M Miller
Nov 2, 2017·The New England Journal of Medicine·Richard S FinkelUNKNOWN ENDEAR Study Group

❮ Previous
Next ❯

Citations

Oct 18, 2018·Current Neurology and Neuroscience Reports·Rocio Garcia-SantibanezRobert C Bucelli
Nov 28, 2019·Proceedings of the National Academy of Sciences of the United States of America·Elie Dolgin
Nov 9, 2019·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Vittoria LombardiAndrea Malaspina
Mar 4, 2020·Expert Opinion on Therapeutic Targets·Elena AbatiStefania Corti
Jun 10, 2020·Annals of Clinical and Translational Neurology·Fen HuangJames D Berry
Jul 4, 2020·Nanomedicine·Jesus Garcia-ChicaRosalia Rodriguez-Rodriguez
Jul 9, 2020·The New England Journal of Medicine·Christian MuellerRobert H Brown
Jul 9, 2020·The New England Journal of Medicine·Timothy MillerToby A Ferguson
Jul 9, 2020·The New England Journal of Medicine·Orla Hardiman, Leonard H van den Berg
Feb 5, 2019·Frontiers in Neurology·Koen Poesen, Philip Van Damme
Jun 17, 2019·Mammalian Genome : Official Journal of the International Mammalian Genome Society·Remya R NairElizabeth M C Fisher
Jun 20, 2020·Nature Reviews. Neuroscience·Peter McColganGeraint Rees
Aug 16, 2018·Nature Reviews. Neurology·Ian Fyfe
May 24, 2019·Neurology. Genetics·Daniel R ScolesStefan M Pulst
Jul 31, 2019·JCI Insight·Gregory J RaymondSonia M Vallabh
Jul 10, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Daniel R Scoles, Stefan M Pulst
Jun 18, 2020·Frontiers in Molecular Neuroscience·Yuan Chao XueHonglin Luo
Jul 14, 2020·Medicinal Research Reviews·Epaminondas Doxakis
May 29, 2020·Nature·Eric Vallabh MinikelDaniel G MacArthur
Jul 25, 2019·Brain : a Journal of Neurology·Julien H ParkThorsten Marquardt
Jul 10, 2019·Annual Review of Neuroscience·C Frank BennettDon W Cleveland
Jun 6, 2019·Der Nervenarzt·Stefan-M Pulst
Dec 20, 2018·Annals of Clinical and Translational Neurology·Wade K SelfTimothy M Miller
Sep 11, 2019·International Journal of Molecular Sciences·Marisa CappellaMaria Grazia Biferi
Aug 7, 2019·Cellular and Molecular Neurobiology·Benedetta PerroneSebastiano Cavallaro
Jul 29, 2020·Nature Communications·Kevin A GuttenplanBen A Barres
Oct 10, 2020·Annual Review of Pharmacology and Toxicology·C Frank BennettDon W Cleveland
Jul 22, 2018·Current Opinion in Neurology·Cindy V Ly, Timothy M Miller
Oct 27, 2020·Expert Opinion on Therapeutic Targets·Tatjana BeutelLucas Schirmer
Dec 16, 2020·Gene Therapy·Burak BerberCihan Tastan
Dec 18, 2020·Frontiers in Cellular Neuroscience·Luke McAlaryNeil R Cashman
Jan 31, 2021·International Journal of Molecular Sciences·Anna YangOrnit Chiba-Falek
Feb 2, 2021·Frontiers in Genetics·Ernesto Canalis
Mar 2, 2021·Neural Regeneration Research·Yuri Matteo FalzoneNilo Riva

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotides
transgenic
SMA
ELISA

Clinical Trials Mentioned

NCT02519036
NCT02623699
NCT03186989

Software Mentioned

Prism6

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating genetic alterations in this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.